TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00842751

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: First Intervention (7 days)
Description: Acyline 300mcg/kg subcutaneous (days 1, 15 \& 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: First Washout (7 days)
Description: Washout of 7 days between each of the 3 treatment arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second Intervention (7 days)
Description: Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Third Intervention (7 days)
Description: Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Second wash-out period
Description: Washout of 7 days between each of the 3 treatment arms
Study: NCT00846092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warp 10 LED Device
Description: Study Subjects will take the Warp 10 (LED) home and treat twice per day for three months

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared light (NIR)
Description: * Subjects will be exposed to light emitted from LED's at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~* Treatments involve application of the LED-generated light for 80 seconds, twice daily.
Study: NCT03843840

Intervention type: DEVICE
Intervention: Combined Coaxial Optical Coherence Tomography
Description: Taking images of the retina with two wavelengths
Study: NCT00093704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib + ganciclovir
Description: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
Study: NCT00463567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol (12 µg b.i.d.)
Description: Formoterol 12 µg twice daily (b.i.d.) in the morning and in the evening via an aerolizer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium (18 µg o.d.)
Description: Tiotropium 18 µg once daily (o.d.) dry powder capsules delivered via a SDDPI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Indacaterol
Description: In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Indacaterol
Description: In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Formoterol
Description: In the morning and in the evening, placebo to formoterol delivered via Aerolizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Formoterol
Description: In the morning and in the evening, placebo to formoterol delivered via Aerolizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Formoterol
Description: In the morning and in the evening, placebo to formoterol delivered via Aerolizer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Formoterol
Description: In the morning and in the evening, placebo to formoterol delivered via Aerolizer.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Formoterol
Description: In the morning and in the evening, placebo to formoterol delivered via Aerolizer.
Study: NCT02721472

Intervention type: PROCEDURE
Group type: OTHER
Intervention: micro- and macro-circulatory vascular remodelling measures not practice in routine care
Description: Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biological measures not practice in routine care
Description: Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, Annexin A5, RNA and TSP1
Study: NCT01794767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,9% NaCl flush
Description: Normal Saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin 50U/ml
Description: Heparin solution
Study: NCT04096599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xylitol toothpaste
Description: At-home preventive measures + xylitol-containing (25%) toothpaste

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste
Description: At-home preventive measures + fluoride (1000 ppm F) toothpaste
Study: NCT05497999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Outreach
Description: The treatment is proactive outreach that sought to enroll individuals in a VBID program available to all enrollees that provided: 1) large reductions in cost-sharing for maintenance inhalers, and 2) telephone-based COPD medication management services.~Proactive outreach for those randomized to the treatment arm included, at a minimum, a phone call and letter in the mail from Humana. Proactive outreach could also have included an email, text message, and/or provider referral.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Proactive Outreach
Description: Control group participants received no proactive outreach but could call to enroll themselves in the VBID program if they learned about it through traditional means, such as the benefits description manual.
Study: NCT01398709

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slow rewarming strategy
Description: Rewarming rate:0.24 degrees C/min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast rewarming strategy
Description: Rewarming rate:0.5 degrees C/min.
Study: NCT03202771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Biofeedback Therapy
Description: Patients will be taught how to use the home-trainer in a single lab session. Then we will place a reusable, dual sensor, probe into their rectum. The probe is connected to a hand- held pressure monitor displaying the patient's response. Next, the clothed patient will be asked to sit on a commode, and attempt 15 bearing down maneuvers. When the anal sphincter pressure decreases more lights go on. If the patient cannot relax then fewer lights go on. Thus, the number of lighted lights gives instant feedback about their performance. Patients will get a 20-minute tape recording for home use. Patients will be asked to insert the probe at least twice daily and each time practice at least 15 bearing down maneuvers; a daily log will be kept. At 4 and 8 weeks, they will return for follow up. Based on their progress, new targets will be set by adjusting the device's sensitivity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Office Biofeedback Therapy
Description: A monitor screen will provide visual feedback by showing changes in pressure activity. First patients will be taught abdominal muscle coordination exercise to improve the pushing effort during defecation. Here, patients are taught how to distend the abdomen by inhaling slowly and then holding their breath for at least 15 seconds and to practice this for 20 minutes, twice a day. Thereafter, patients will be asked to attend the motility laboratory, biweekly for up to 6 training sessions. Biofeedback Therapy (BT) will be performed by a 3-sensor manometry probe. The clothed patient will be seated on a commode in front of a monitor. The physician/nurse therapist will give verbal feedback by either complimenting the patient for performing a correct maneuver or rectifying any errors. Each 60 minute treatment session will comprise of the following maneuvers:
Study: NCT03877328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BiotechCoachForAll
Description: A group of thirty subjects diagnosed with heart failure (HF) of any etiology undergo an experimental procedure in the following order: resting-state (eyes-closed), passively viewing thirty two agents which are grouped with respect to different appearance characteristics and passively viewing combinations of virtual agents. During the experiment, brain activity, heart rate, skin conductance, temperature and eye-gaze biosignals are collected by means of electroencephalography, Empatica E4 and Gazepoint. Subsequently, a prospective cohort study is performed in a subgroup of ten participants which undergo a three additive stage procedure. Stage 1, a wearable monitoring device (Wavelet Health) is given in order to provide objective information on the patient's activity. Stage 2, the FitForAll physical exercise program is introduced. Stage 3, introduces the coaching aspects, where personalized recommendations and suggestions are delivered through home surfaces' projection.
Study: NCT02532738

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Routine Treatment of CD
Description: The Drug including 6MP, AZA, infliximab and thalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine Treatment of CD
Description: The Drug including 6MP, AZA, infliximab and thalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine Treatment of CD
Description: The Drug including 6MP, AZA, infliximab and thalidomide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC treatment 01
Description: Injection of 3×10E6/kg of MSC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC treatment 02
Description: Injection of 6×10E6/kg of MSC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NS
Description: Injection of NS
Study: NCT03868813

Intervention type: BEHAVIORAL
Intervention: Semi-structured Interview
Description: One-on-one semi-structured interviews

Intervention type: BEHAVIORAL
Intervention: Semi-structured Interview
Description: One-on-one semi-structured interviews
Study: NCT01875406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic exercises
Study: NCT02417506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-OA-07 (Lanconone)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study: NCT04052633

Intervention type: RADIATION
Intervention: intraoperative cholangiography
Description: success or failure of cholangiography

Intervention type: RADIATION
Intervention: intraoperative cholangiography
Description: success or failure of cholangiography
Study: NCT02696967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLR325
Description: CLR325 Concentrate for solution for infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT02631590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered once as intravenous (IV) infusion over 60 minutes. Treatment is on Days 1 and 8 every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered as 30-min IV infusion. Treatment is on Days 1 and 8 every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Experimental Drug: Copanlisib administered as an IV over 60-minutes beginning 1 hour after completing gemcitabine infusion. Treatment is on Days 1 and 8 every 21 days.
Study: NCT02789293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeOP1 device
Description: Ultrasound Ciliary Plasty (UCP procedure) using Focused Ultrasound
Study: NCT04688008

Intervention type: DRUG
Group type: OTHER
Intervention: Hetrombopag
Description: Drug: Early phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions~Drug: Late phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions

Intervention type: DRUG
Group type: OTHER
Intervention: Hetrombopag
Description: Drug: Early phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions~Drug: Late phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions
Study: NCT03668899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irrigation
Description: irrigation of root canals during mechanical preparation for pueposes of cleaning and disinfection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irrigation
Description: irrigation of root canals during mechanical preparation for pueposes of cleaning and disinfection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irrigation
Description: irrigation of root canals during mechanical preparation for pueposes of cleaning and disinfection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: irrigation
Description: irrigation of root canals during mechanical preparation for pueposes of cleaning and disinfection
Study: NCT02351856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor, oral
Description: multiple dose, single schedule
Study: NCT04685044

Intervention type: DEVICE
Group type: OTHER
Intervention: IH 1Tx32Rx Head Array
Description: BrainPET insert
Study: NCT02341677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SmartTarget - Biopsy
Description: MRI to ultrasound fusion guided prostate biopsy
Study: NCT00214890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: 300 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir
Description: 600 mg once daily
Study: NCT01450332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee-T-Nol
Description: The ACL prosthesis is intended for the treatment of ruptured ACL. It will be used as an implant to replace the native, torn ACL. Implantation will be done using arthroscopy
Study: NCT01772316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: 162 mg subcutaneously weekly or every two weeks, 96 weeks
Study: NCT01262196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP4OX
Description: 4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline (0.9%) solution
Study: NCT03622788

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-treated Veto Cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSCT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT03164239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group - telephone and print exercise intervention
Description: Intervention has previously been described.
Study: NCT03249116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animal-assisted intervention
Description: Interaction with a therapy dog

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animal-assisted intervention
Description: Interaction with a therapy dog

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active control
Description: Interaction with a stuffed dog
Study: NCT01235078

Intervention type: DEVICE
Intervention: EZ-IO
Description: powered intraosseous vascular access system
Study: NCT01177397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223
Description: Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
Study: NCT03169725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strain)
Description: Investigational IPV based on Sabin strain (LBVC). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strain)
Description: Investigational IPV based on Sabin strain (LBVC). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strain)
Description: Investigational IPV based on Sabin strain (LBVC). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Poliomyelitis Vaccine (Salk strain)
Description: Commercialized IPV based on Salk strain (Imovax Polio). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
Study: NCT01318239

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DCE MRI
Description: MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).~MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE MRI
Description: MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).~MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy.
Study: NCT04867304

Intervention type: OTHER
Intervention: Patient education about chronic pancreatitis.
Description: Patients in the second cohort were educated about their disease phenotype in a structured and personalised manner that included their disease course, symptoms, imaging, treatment option and possible long-term outcomes and prognosis. This was followed by answering all the queries of the patient and their caregivers.~The patients were advised to visit the Pancreas clinic after 3-months for re-evaluation of the clinical, psychological and metabolic parameters.

Intervention type: OTHER
Intervention: Patient education about chronic pancreatitis.
Description: Patients in the second cohort were educated about their disease phenotype in a structured and personalised manner that included their disease course, symptoms, imaging, treatment option and possible long-term outcomes and prognosis. This was followed by answering all the queries of the patient and their caregivers.~The patients were advised to visit the Pancreas clinic after 3-months for re-evaluation of the clinical, psychological and metabolic parameters.
Study: NCT00329589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade (bortezomib)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade (bortezomib)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade (bortezomib)
Study: NCT01039376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose was 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years.

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Observation/Safety Evaluation
Study: NCT00563472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estetrol
Description: 10 mg orally per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estetrol
Description: 20 mg orally per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estetrol and desogestrel
Description: 20 mg estetrol and 150 microg desogestrel orally per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estetrol and progesterone
Description: 20 mg estetrol and 200 mg progesterone orally per day for 28 days
Study: NCT03252925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 50mg/Kg.d, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 50mg/Kg.d, oral
Study: NCT00458978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01635426

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 75 mg daily for 2 months after meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg daily for 2 months after meals